Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02088775 · ClinicalTrials.gov registry record · NA
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
A NA study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT02088775 is a NA study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 44 participants.
The verdict
NCT02088775, a NA study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
This clinical trial studies positron emission tomography (PET)-computed tomography (CT) in determining the radiation dose delivered with radioactive spheres to patients with liver metastasis or primary liver or biliary cancer. Comparing results of diagnostic procedures dose before and after delivery of radioactive spheres to the liver may help determine radioembolization dose and plan the best treatment for liver metastasis or primary liver or biliary cancer.
Interventions
- PROCEDURE CT Scan
- PROCEDURE PET scan
- PROCEDURE hepatic artery embolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-02 |
| Est. Completion | 2021-07-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02088775
The ClinicalTrials.gov registry entry for NCT02088775 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CT Scan is the first listed.
NCT02088775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02088775 about?
NCT02088775 is a clinical study titled "PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer". This clinical trial studies positron emission tomography (PET)-computed tomography (CT) in determining the radiation dose delivered with radioactive spheres to patients with liver metastasis or primary liver or biliary cancer. Comparing results of diagnostic procedures dose before and after delivery...
What is the current status of trial NCT02088775?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2014-02. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT02088775?
The interventions under investigation include: CT Scan (PROCEDURE), PET scan (PROCEDURE), hepatic artery embolization (PROCEDURE).
Who is sponsoring clinical trial NCT02088775?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.